학술논문

Switch to fulvestrant and palbociclib versus no switch in advanced breast cancer with rising ESR1 mutation during aromatase inhibitor and palbociclib therapy (PADA-1): a randomised, open-label, multicentre, phase 3 trial
Document Type
Article
Source
In: The Lancet Oncology. (The Lancet Oncology, November 2022, 23(11):1367-1377)
Subject
Language
English
ISSN
14745488
14702045